Orphalan announces FDA acceptance for filing of New Drug Application (NDA) for trientine tetrahydrochloride (TETA 4HCl) for the treatment of Wilson’s Disease —NDA supported by positive data from Phase 3…
JUNE 25, 2021 - ORPHAN DISEASES — CHELATE trial confirmed trientine tetrahydrochloride was non-inferior to d-Penicillamine and met the primary endpoint of Non-Ceruloplasmin Copper (NCC) levels as a maintenance therapy…
At Orphalan we identify, develop and provide access to innovative treatments for patients with rare diseases. The information available on this Website is for information purposes only.
We work in a highly-regulated industry with unique legal considerations. Medical and health information may be presented but the content we share is not intended to provide professional medical advice, diagnosis or treatment.
Always seek medical advice from qualified health care professional for any questions you may have regarding your medical condition.
To report an adverse event experience for any Orphalan product please contact us by writing to AdverseEventReporting@orphalan.com or calling direct: +356 2776 1718, or calling the local toll free telephone number listed under your country and choosing option 3.
226 Boulevard Voltaire
Tel : +33 (0)1 42 49 82 64